ProShare Advisors
STLN

ProShare Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

ProShare Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.5K Sell
11,561
-908
-7% -$2.78K ﹤0.01% 1810
2025
Q4 		$44.4K Buy
12,469
+2,208
+22% +$8.19K ﹤0.01% 1969
2025
Q3 		$35.8K Sell
10,261
-1,843
-15% -$6.32K ﹤0.01% 1960
2025
Q2 		$24.8K Buy
+12,104
New +$30.3K ﹤0.01% 2055

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's STLN Position: Q1 2026 in Review

ProShare Advisors reduced its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 7.3% in Q1 2026, selling an estimated $2.78K and leaving 11,561 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1810.

ProShare Advisors first reported a position in STLN in Q2 2025 and has held it in 4 quarters since. The position peaked at $44.4K in Q4 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • ProShare Advisors held 11,561 shares of Starling Oncology Institute, Inc. Common Stock worth $35.5K as of Q1 2026.
  • ProShare Advisors sold 908 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $2.78K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of ProShare Advisors's portfolio in Q1 2026, its #1810 holding.
  • ProShare Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2025 and has held it in 4 quarters since.
  • ProShare Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $44.4K in Q4 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.